Invicorp

Phentolamine mesilate, the active ingredient in Invicorp, is a Alpha-adrenergic antagonist presented as an injectable solution for intracavernous use. It is combined with aviptadil, a vasoactive intestinal peptide analog, to treat erectile dysfunction in adult males. GNH USA supplies Invicorp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Invicorp, containing phentolamine mesilate and aviptadil, is used in the management of erectile dysfunction.

- Erectile dysfunction: improves penile erection by enhancing blood flow to the corpora cavernosa. - Penile vascular insufficiency: promotes vasodilation of penile arteries to support adequate perfusion. - Post‑surgical penile rehabilitation: aids recovery of erectile function after procedures affecting penile blood supply.

Adverse reactions may occur with intracavernous administration of Invicorp.

Common Side Effects: - Penile pain or discomfort. - Local bruising or hematoma at injection site. - Headache. - Flushing. - Dizziness. - Transient hypotension.

Serious or Rare Side Effects: - Priapism lasting longer than four hours. - Severe hypotension with syncope. - Allergic reaction including rash, itching, or anaphylaxis. - Cardiovascular events such as myocardial infarction. - Vision changes or ocular disturbances. - Hematuria or urinary retention.

Before using Invicorp, consider the following safety measures.

- Cardiovascular disease: avoid if uncontrolled hypertension or recent myocardial infarction. - Bleeding disorders: use with caution in patients on anticoagulants. - Concurrent alpha‑blockers: monitor for additive hypotensive effects. - Allergy history: assess for hypersensitivity to phentolamine, aviptadil, or formulation excipients. - Pregnancy and lactation: safety not established; avoid use. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Invicorp may interact with other medications.

Major Interactions (Avoid): - Oral or intravenous alpha‑adrenergic antagonists: risk of profound hypotension. - Nitrates: additive vasodilatory effect leading to severe blood pressure drop. - Phosphodiesterase‑5 inhibitors: increased risk of priapism.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may require dose adjustment. - Anticoagulants/antiplatelet drugs: heightened bleeding risk at injection site. - CYP450 modulators: potential impact on aviptadil metabolism.